Vontobel Holding Ltd. Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Vontobel Holding Ltd. increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,089,103 shares of the medical research company’s stock after buying an additional 46,743 shares during the period. Thermo Fisher Scientific accounts for about 1.4% of Vontobel Holding Ltd.’s investment portfolio, making the stock its 21st biggest position. Vontobel Holding Ltd.’s holdings in Thermo Fisher Scientific were worth $441,588,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TMO. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Capital Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 2.4% during the first quarter. Capital Investment Advisors LLC now owns 1,367 shares of the medical research company’s stock worth $680,000 after acquiring an additional 32 shares during the last quarter. Daymark Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 31.5% during the first quarter. Daymark Wealth Partners LLC now owns 776 shares of the medical research company’s stock worth $386,000 after acquiring an additional 186 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Thermo Fisher Scientific by 27.9% during the first quarter. Farther Finance Advisors LLC now owns 5,048 shares of the medical research company’s stock worth $2,438,000 after acquiring an additional 1,100 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on TMO shares. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays increased their price objective on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a report on Friday, July 11th. Hsbc Global Res lowered Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $590.60.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $536.21 on Thursday. The business’s 50-day moving average is $486.09 and its two-hundred day moving average is $448.21. The company has a market capitalization of $202.48 billion, a P/E ratio of 31.01, a P/E/G ratio of 2.93 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Activity

In other news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.